7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Oxazinone derivatives according to Formula I, are disclosed as covalent inhibitors of mutant forms of isocitrate dehydrogenase (IDH1 and IDH2). The derivatives or pharmaceutical composition containing the derivative, are suitable for use in treating cancer which expresses IDH1 or IDH2

Saved in:
Bibliographic Details
Main Authors Gilmour, Raymond, Rankovic, Zoran, Burkholder, Timothy Paul, Bauer, Renato Alejandro, Boulet, Serge Louis, Hahn, Patric James
Format Patent
LanguageEnglish
Published 30.07.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Oxazinone derivatives according to Formula I, are disclosed as covalent inhibitors of mutant forms of isocitrate dehydrogenase (IDH1 and IDH2). The derivatives or pharmaceutical composition containing the derivative, are suitable for use in treating cancer which expresses IDH1 or IDH2
Bibliography:Application Number: NZ20170754115